Merck (MRK) Capital Expenditures (2009 - 2026)
Merck (MRK) posted quarterly Capital Expenditures of $991.0 million for Q1 2026, down 25.38% year-over-year from $1.3 billion in Q1 2025, and down 4.07% quarter-over-quarter from $1.0 billion in Q4 2025.
Merck (MRK) Capital Expenditures (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Capital Expenditures for 18 consecutive years, with $991.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 25.38% year-over-year to $991.0 million; the TTM figure through Mar 2026 stood at $3.8 billion (down 1.67% YoY), while the FY2025 annual figure was $4.1 billion, up 21.95% from the prior year.
- Capital Expenditures slipped to $991.0 million in Q1 2026 per MRK's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.3 billion in Q1 2025 and bottomed at $764.0 million in Q2 2025.
- Historically, Capital Expenditures has averaged $983.9 million across 5 years, with a median of $987.0 million in 2025.
- Annual changes were most pronounced in 2025 — Capital Expenditures jumped 54.24% — and 2026, when it slipped 25.38%.
- Merck's Capital Expenditures stood at $1.1 billion in 2022, then slipped by 13.93% to $989.0 million in 2023, then decreased by 5.26% to $937.0 million in 2024, then advanced by 10.25% to $1.0 billion in 2025, then fell by 4.07% to $991.0 million in 2026.
- Business Quant data shows MRK's Capital Expenditures at $991.0 million in Q1 2026, $1.0 billion in Q4 2025, and $987.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.03 Bn | 631.27 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.49 Bn | 462.92 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 375.14 Bn | 368.00 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 302.92 Bn | 295.23 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.73 Bn | 252.83 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 236.80 Bn | 222.81 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.42 Bn | 179.24 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.16 Bn | 101.99 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.18 Bn | 47.80 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 893.00 Mn |
| Jun 30, 2026 | 893.00 Mn |
| Mar 31, 2026 | 991.00 Mn |
| Mar 31, 2026 | 991.00 Mn |
| Dec 31, 2025 | 1.03 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 987.00 Mn |
| Sep 30, 2025 | 987.00 Mn |
| Jun 30, 2025 | 764.00 Mn |
| Jun 30, 2025 | 764.00 Mn |
| Mar 31, 2025 | 1.33 Bn |
| Mar 31, 2025 | 1.33 Bn |
| Dec 31, 2024 | 937.00 Mn |
| Dec 31, 2024 | 937.00 Mn |
| Sep 30, 2024 | 783.00 Mn |
| Sep 30, 2024 | 783.00 Mn |
| Jun 30, 2024 | 791.00 Mn |
| Jun 30, 2024 | 791.00 Mn |
| Mar 31, 2024 | 861.00 Mn |
| Mar 31, 2024 | 861.00 Mn |